consortium of companies

Consortium.AI is a biotechnology company established as a joint venture between Insilico Medicine and A2A Pharmaceuticals to revolutionize drug discovery for rare diseases. The company utilizes a proprietary artificial intelligence platform that combines Insilico's deep learning-based target discovery with A2A's SCULPT chemical design technology. Its lead programs are focused on developing novel small molecule therapeutics for Duchenne Muscular Dystrophy (DMD) and other orphan indications. By integrating these advanced computational tools, Consortium.AI aims to significantly accelerate the timeline and reduce the costs associated with bringing new treatments to patients with high unmet needs. The company is headquartered in Rockville, Maryland, and operates as a specialized vehicle for the collaborative efforts of its parent organizations.